Dr. Yiping Zhu 朱一平
Chief Physician, Associate Professor
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of urinary system tumors, with a focus on bladder cancer. Expertise includes early diagnosis, minimally invasive surgery, robotic and laparoscopic radical cystectomy with orthotopic neobladder, bladder-preserving therapy for invasive cancer, and comprehensive care for advanced bladder cancer, renal pelvis cancer, and ureteral cancer.
Dr. Zhu holds an MD and is a Chief Physician and Associate Professor at Fudan University Shanghai Cancer Center, where they have worked since 2007. A certified da Vinci robotic surgeon and former visiting scholar at the University of Strasbourg, France, Dr. Zhu leads the bladder cancer subspecialty group and performs nearly 1,000 bladder cancer surgeries annually.
Professional roles
- Member, Bladder Cancer and Immunotherapy Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Bladder Cancer Expert Committee, China Anti-Cancer Association
- Member, Editorial Board for Bladder Cancer Guidelines, Chinese Urological Association
- Member, Immunotherapy Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhu Yiping). Papers usually list the name as Yiping Zhu or Zhu Y.
Selected publications
67 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Immunother Cancer, 2025 (senior author): Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer. PubMed 41314976
- Cancer Cell Int, 2024 (senior author): Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75. PubMed 38570787
- Front Oncol, 2021 (senior author): ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer. PubMed 34868963
- Cell Death Dis, 2021 (senior author): LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. PubMed 34728613
- BMC Cancer, 2021 (senior author): Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation. PubMed 34315433
- J Cell Mol Med, 2021 (senior author): Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. PubMed 33797188
- Front Oncol, 2021 (senior author): Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. PubMed 33842349
- Front Surg, 2021 (senior author): Intravesical Recurrence After Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes. PubMed 33693025
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion